Antigenics

Source: news.yahoo.com --- 106 days ago
Reuters - Russian regulators have approved the world's first cancer vaccine, validating an unusual strategy by its maker to introduce the product even though it failed a late-stage clinical trial. ...

Source: news.google.com --- 106 days ago
Javno.hr Antigenics Kidney Treatment Wins Approval in Russia Wall Street Journal - 44 minutes ago By JOHN FLOWERS Biotechnology firm Antigenics Inc. said Tuesday its treatment for kidney cancer received regulatory approval in Russia, the first in any country for the cancer vaccine. Antigenics says kidney cancer drug approved by Russian health ... Forbes Antigenics' Oncophage Granted Registration Certificate In Russia ... RTT News Reuters India  - Pharma Times (subscription)  - Business Wire (press release)  - Reuters all 29 news articles ...

Source: www.moreover.com --- 104 days ago
) BeaconEquity.com announces the publication of 'Antigenics Inc.'s (AGEN) Therapeutic Cancer Vaccine 'Oncophage' Approved in Russia' Investors can view all of the investment articles for free by visiting: http://www.BeaconEquity. ...

Source: www.moreover.com --- 106 days ago
(FinancialWire) The Russian Ministry of Public Health has issued a registration certificate for the use of Antigenics Inc.'s (NASDAQ: AGEN) (Current Market Cap: US$ 139.77 Mil. ...

Source: www.moreover.com --- 107 days ago
BOSTON (Reuters) - The tiny biotechnology company Antigenics Inc said on Tuesday it has won approval to market its kidney cancer vaccine, Oncophage, in Russia, making it the only cancer vaccine available in the world. ...

Source: www.moreover.com --- 104 days ago
Antigenics has announced that the Russian Ministry of Public Health has issued a registration certificate for the use of Oncophage in the treatment of kidney cancer patients at intermediate risk for disease recurrence. ...

Source: www.moreover.com --- 107 days ago
Extract not available. ...

Source: www.moreover.com --- 106 days ago
Oncophage Granted Registration Certificate In Russia For Treatment Of Kidney Cancer Patients At Intermediate Risk - Update Free Report! The Only 3 You'll Ever Need Win Over $12,000 in Cash Prizes Predicting the Direction of a Stock! ...

Source: online.wsj.com --- 106 days ago
Antigenics said its treatment for kidney cancer received regulatory approval in Russia – the first in any country for the biotechnology firm's cancer vaccine. ...

Source: www.businesswire.com --- 84 days ago
NEW YORK--(BUSINESS WIRE)--Antigenics Inc. (NASDAQ: AGEN) reported results today for the quarter ended March 31, 2008. The company incurred a net loss attributable to common stockholders of ...

Source: en.rian.ru --- 106 days ago
...

Source: seekingalpha.com --- 105 days ago
Mike Huckman submits: Tuesday morning, a little biotech company, Antigenics (AGEN), announced that Russia has approved its kidney cancer drug, Oncophage. It's the first so-called therapeutic cancer vaccine to win full-out approval anywhere in the world. This is not a traditional preventive vaccine where you'd get a shot to stave off coming down with something. Therapeutic means you'd unfortunately have to get the cancer first and then your own cells are mixed with the "vaccine" to empower your body's immune system to fight off the disease. Complete Story » ...

Source: seekingalpha.com --- 105 days ago
Kirk Lindstrom submits: Yesterday, Antigenics Inc. (NASDAQ: AGEN) announced that the Russian Ministry of Public Health has issued a registration certificate for the use of Oncophage® (vitespen) in the treatment of kidney cancer patients at intermediate risk for disease recurrence. Antigenics expects to launch Oncophage in Russia in the second half of 2008. click to enlarge images Complete Story » ...

Source: seekingalpha.com --- 104 days ago
Antigenics (AGEN) got Russian approval for its cancer immunotherapy - a cancer "vaccine" is the sexy, headline grabbing term. This also created a few seconds of buzz around two other immunotherapy companies, Dendreon (DNDN) and Cell Genesys (CEGE). I mention these two other companies because, for purposes of full disclosure, I own CEGE stock and recommend it in my newsletter service. I also own a full hedged position of DNDN I cannot wait to liquidate when my hedge expires. In the U.S., AGEN has been failing to get approvals from the FDA for good reasons - their treatment, Oncophage, did not work in Phase III trials - it did not even come close, which is at least a sort of argument DNDN could and did make. Oncophage targets kidney cancer and was shown to work within a sub group of patients with "lower-stage tumors" and therefore a better shot at survival - and 45% of these patients responded to Oncophage. Hence, the approval in a Russia looking to build new industries. Complete Story » ...

Source: www.einnews.com --- 105 days ago
...

Source: www.streetinsider.com --- 106 days ago
Visit StreetInsider.com at http://www.streetinsider.com/FDA/Antigenics+%28AGEN%29+Higher+After+Russia+Approves+Oncophage+for+Kidney+Cancer/3527196.html for the full story. ...

Source: www.247wallst.com --- 105 days ago
Antigenics Inc. (NASDAQ: AGEN) has announced this morning that it has entered into definitive agreements to sell 7 million shares of its common stock at a price of $3.00 per share in a private placement. The gross proceeds to the company will be $21 million before deducting filing and placement fees. The investors buying into this private placement are also receiving five-year warrants to purchase up to an additional 7 million shares of common stock at an exercise price of $3.75 per share. Rodman & Renshaw is acting as the exclusive placement agent for this offering. The company noted that... ...